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INTRODUCTION
Ocular allergies constitute a heterogeneous group of frequently 
recurrent inflammatory diseases of the ocular surface, ranging from 
mild to severe manifestations. Allergic conjunctivitis encompasses 
seasonal conjunctivitis, perennial conjunctivitis, atopic keratocon-
junctivitis (AKC), vernal keratoconjunctivitis (VKC), and giant papillary 
conjunctivitis(1). AKC and VKC are the most severe forms due to po-
tential visual impairment caused by corneal scarring, irregular astig-
matism, and keratoconus(2-3). Although glaucoma and cataract secon-
dary to corticotherapy also represent potential causes of blindness, 
some patients show such severe clinical presentation and recurrence 
that the use of glucocorticosteroids is required to control the disease.
The treatment of ocular allergies involves the use of preventive 
measures such as avoiding exposure to specific and nonspecific 
agents that trigger the allergy, and the use of topical and/or systemic 
drugs. Milder cases can be treated with cold compresses, preservati-
ve-free artificial tears, topical nonsteroidal anti-inflammatory drugs, 
and topical antihistamines/mast cell stabilizers. More severe cases 
are treated with an association of antihistamines/mast cell stabilizers 
and topical or systemic corticosteroids, either as intensive short-term 
therapy or as long-term treatment regimes. The use of immunomo-
dulators such as cyclosporine A and tacrolimus is reserved for cases 
of steroid-dependent allergic keratoconjunctivitis due to the known 
side effects of long-term use of steroids, or when the use of corticoste-
roids is contraindicated. Surgical treatment such as resection of the 
giant papillae may be used in severe cases in which there is persistent 
corneal injury(4,5).
Some patients demonstrate difficult disease control even when 
on systemic immunosuppressors, perhaps due to discontinuation or 
low adherence to the treatment, considering its high frequency of 
administration and/or high cost.
Supratarsal injection of triamcinolone for severe vernal  
keratoconjunctivitis in children
Injeção supratarsal de triancinolona na ceratoconjuntivite primaveril grave em crianças
AlexAndre xAvier dA CostA1, José ÁlvAro PereirA Gomes2, leonArdo Guedes CAndido mArCulino1, verA luCiA liendo1,  
telmA PereirA BArreiro1, myrnA serAPião dos sAntos1
 Submitted for publication: May 9, 2016
 Accepted for publication: January 16, 2017
1 Cornea and External Eye Disease Clinic, Departamento de Oftalmologia, Universidade Federal de 
São Paulo, São Paulo, SP, Brazil. 
2 Advanced Ocular Surface Center, Departamento de Oftalmologia, Universidade Federal de São 
Paulo, São Paulo, SP, Brazil. 
 Funding: No specific financial support was available for this study.
 Disclosure of potential conflicts of interest: None of the authors have any potential conflict of 
interest to disclose.
 Corresponding author: Alexandre X. Costa. Escola Paulista de Medicina. Rua Botucatu, 821 - 
04023-062 - 1o andar - São Paulo, SP, Brazil - E-mail: dr.alexandre.x@gmail.com
 Approved by the following research ethics committee: Universidade Federal de São Paulo (UNI-
FESP) (# 0357/09).
ABSTRACT
Purpose: To evaluate the use of supratarsal injection of triamcinolone acetonide 
in severe vernal keratoconjunctivitis (VKC) in children.
Methods: Patients included in this open clinical trial were those with severe 
VKC-associated with keratitis, gelatinous limbal infiltrates, and/or giant papillae, 
with a history of recurrence and resistance to conventional topical antiallergic 
agents. Patients were treated with a supratarsal injection of 20 mg triamcino-
lone acetonide. 
Results: Analysis included 27 injections in 23 eyes of 17 patients with severe 
allergic keratoconjunctivitis. Mean age was 12.3 (range: 7-19) years. Mean 
follow-up time was 39.3 months (SD=19.21). In the 17 patients, the disease was 
successfully controlled for an average of 3.6 months (range: 1-16), during which 
allergy symptoms and signs were significantly improved, with complete resolution 
of lid edema and conjunctival chemosis, significant decline of pannus and keratitis, 
and reduction of giant papillae size. 
Conclusion: Treatment of severe, acute VKC in children with supratarsal injection 
of 20 mg triamcinolone acetonide showed satisfactory results and was well tolerated 
by patients; it may therefore constitute a safe option for severe and challenging 
cases. While full disease remission was not achieved, a significant improvement 
was found in ocular allergy symptoms and signs, with a reduction in the frequency 
of acute recurrences.
Keywords: Eyelids/drug effects; Keratoconjunctivitis/drug therapy; Conjuncti-
vitis, allergic/drug therapy; Injections; Triamcinolone acetonide/administration 
& dosage
RESUMO
Objetivo: Avaliar o uso da injeção supratarsal de triancinolona na ceratocon junti vite 
primaveril grave (VKC) em crianças. 
Métodos: Pacientes com VKC grave associada à ceratite, limbo gelatinoso e/ou pa-
pilas gigantes, com história de recidivas e resistência a agentes antialérgicos tópicos 
convencionais foram incluídos neste ensaio clínico. Os pacientes foram tratados com 
injeção de 20 mg de acetato de triancinolona supratarsal. 
Resultados: A análise incluiu 23 olhos de 17 pacientes com ceratoconjuntivite 
alérgica grave. A idade média foi de 12,3 com intervalo de 7-19 anos. O tempo médio 
de acompanhamento foi de 39,3 meses (DP 19,21). Dos 17 pacientes, a doença foi 
controlada com sucesso por uma média de 3,6 meses (intervalo 1-16) em que os sinais 
e sintomas foram significativamente melhorados com resolução completa do edema 
palpebral e quemose conjuntival, redução significativa de pannus, ceratite e redução 
do tamanho das papilas gigantes. 
Conclusão: O tratamento da VKC grave em crianças com injeção supratarsal de 20 mg 
de acetato de triancinolona mostrou resultados satisfatórios, sendo bem tolerada pelas 
crianças às quais foram submetidas, podendo constituir uma opção segura para casos 
graves e difíceis de VKC. Uma melhora significativa foi encontrada nos sinais e sintomas 
alérgicos oculares, com diminuição da frequência de recidivas agudas, no entanto sem se 
mostrar efetiva para a completa remissão da doença.
Descritores: Pálpebras/efeitos de drogas; Ceratoconjuntivite/quimioterapia; Con-
juntivite alérgica/quimioterapia; Injeções; Triancinolona acetonida/administração 
& dosagem
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Successful management of refractory VKC with supratarsal injec-
tion of corticosteroids has been reported(3,6-9). The current study tes-
ted supratarsal injection of triamcinolone acetonide as a treatment 
option in difficult cases of recalcitrant VKC in children.
METHODS
This prospective study evaluated the supratarsal injection of 
20 mg triamcinolone acetonide in children with severe VKC, defined 
as the presence of recurrent ocular surface inflammation characte-
rized by diffuse punctate keratitis or repetitive shield ulcers, gelatinous 
limbal infiltration, and/or giant papillae on the tarsal conjunctiva.
The sample consisted of children who were not responding or 
inadequately responding to topical therapy with topical antiallergic 
treatment (olopatadine 0.2% once per day or 0.1% twice daily, or 
epinastine 0.05% twice daily) and preservative-free tear substitutes, 
and who had suffered recent deterioration in signs and symptoms 
following discontinuation of topical corticosteroid therapy (0.1% 
dexamethasone or 1% prednisolone 4 times daily with gradual re-
duction of 1 drop every 5 days).
Patients under 7 years of age; those with diseases leading to 
scarring of the conjunctiva, infectious corneal ulcer, and history of 
herpetic keratitis; those who had been submitted to surgical excision 
of giant papillae on the tarsal conjunctiva; and those who wear con-
tact lens were excluded from the study. 
This study was designed at the Cornea and External Eye Disease 
Sector, Department of Ophthalmology, Federal University of São 
Paulo, Brazil, from January 2009 to December 2014, and was appro-
ved by the institute’s Internal Review Board (reference #0357/09). All 
participants and/or their legal guardians received information on the 
study and signed informed consent forms.
After applying topical anesthesia using 1% tetracaine hydro-
chloride, the upper lid was gently everted. Using a 25-gauge needle, 
0.25 mL of lidocaine 2% was injected into the supratarsal space 
between the conjunctiva and Muller’s muscle, approximately 1 mm 
above the superior tarsal border (Figure 1). Following the anesthesia, 
20 mg triamcinolone acetonide was injected in the same potential 
space.
Patients received injections only in the eye(s) that showed 
recurring inflammation when topical corticosteroids were disconti-
nued. After the application, each patient continued with the topical 
treatment that was already being used (e.g., olopatadine hydro-
chloride 0.2%, epinastine hydrochloride 0.05%, tacrolimus 0.03%, 
and carboxymethyl cellulose 0.5%). Topical corticosteroids were 
discontinued after injection.
Patients were evaluated at intervals of 1 day, 1 week, 2 weeks, and 
1 month; they were then followed up monthly until 6 months after 
the injection, or whenever necessary (e.g.; when a new crisis arose). 
Treatment success was defined as a general reduction of symptoms 
and signs; for example, reduced cobblestone papillae size, gelatinous 
limbal infiltrates, and keratitis; clear conjunctiva; and decrease in 
Horner-Trantas dots and inflammation (lid edema, chemosis, pannus, 
and hyperemia). Disease recurrence was determined if symptoms 
and signs increased and attained or exceeded pre-treatment levels 
according to the patient’s records and referral; in this case, reinjec-
tions were an option. 
At each visit, patients underwent a detailed ophthalmic evalua-
tion, including visual acuity, intraocular pressure (IOP) measurement, 
and slit-lamp biomicroscopy examination. Dilated fundus examina-
tion was performed at first visit and repeated as needed. The eyes 
were photographed for later comparison. Side effects following the 
steroid injection were closely observed; these included raised IOP, 
ptosis, infections, conjunctival scarring, and motility disturbance. 
RESULTS
Twenty-seven injections were performed in 23 eyes of the 17 
patients with severe VKC included in this study. Of these patients, 14 
(82.3%) were male and 3 (17.7%) female. Mean patient age was 12.3 
(SD=3.65; range: 7-19 years). Age of onset of symptoms associated 
with keratoconjunctivitis was 5.9 years (SD=3.29; range: 1-13 years). 
All patients were diagnosed with VKC: 7 patients (41.2%) with the 
palpebral form and 10 (58.8) with the mixed form (palpebral and 
limbal). Almost all patients (94.1%) had associated atopy, of which 
16 patients (94.1%) had rhinitis, 5 (29.4%) had asthma, 4 (23.5%) had 
bronchitis, and 8 (47.0%) had dermatitis. The main signs observed 
were as follows: keratitis (100%), cobblestone papillae (88.2%), 
Trantas dots (52.9%), gelatinous limbal infiltrates (47%), and shield 
ulcer (47%) (Table 1).
The mean follow-up time was 39.3 months (SD=19.21). Of the 17 
patients, acute crisis was successfully controlled with remission of signs 
and symptoms in all (100%) for an average of 3.6 months (range: 
1-16; SD=3.87). Complete resolution of lid edema and conjunctival 
chemosis, significant decline of keratitis and pannus, and reduction 
of giant papillae size with marked applanation were demonstrated 
in all patients (Figure 2). However, in 6 patients (35%), the disease 
was controlled for only one month following injection, 2 had severe 
recurrence of the ocular allergy and received systemic immunosup-
pression to control the disease, and 2 had repeated shield ulcers and 
underwent surgical resection of the giant papillae. 
Of the 17 patients, re-injection of triamcinolone due to worse-
ning of the allergy was required in 6 (35%), 1 refused, and the other 
5 were re-injected only in the affected eye; mean time between the 
Table 1. Demographic data and clinical features of patients (n=17)
VKC patients (n) Mean ± SD
Age of injection (years) 7-19 12.3 ± 3.65
Age of onset 1-13 05.9 ± 3.29
Gender %
Male 14 082.3
Female 03 017.7
Associated atopy 16 094.1
Rhinitis 16 094.1
Asthma 05 029.4
Bronchitis 04 023.5
Dermatitis 08 047.0
VKC clinical presentation
Palpebral 07 041.2
Mixed 10 058.8
Signs involved
Cobblestone papillae 15 088.2
Gelatinous limbal infiltrates 08 047.0
Keratitis 17 100.0
Shield Ulcer 08 047.0
Tantras dots 09 052.9
Figure 1. Injection site approximately 0.5-1 mm above the superior tarsal border in 
potential space between conjunctiva and Muller’s muscle.
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first and second injection was 13.1 months (range: 2-38; SD=12.37). 
The remaining patients eventually experienced recurrences of the 
ocular allergy but in a milder form that could be controlled with 
topical drugs. No patients experienced complete disease remission. 
One patient showed increasing IOP, which rose from 11 to 16 mmHg 
after 4 days of the triamcinolone injection (Table 2).
DISCUSSION
The treatment of patients with severe VKC involves-in addition to 
topical antiallergic drugs and artificial tears-the use of corticosteroid 
eye drops with their accompanying side effects such as cataract and 
glaucoma(4). 
Treatment of such cases remains a challenge, and the supratar-
sal injection of triamcinolone acetate is an interesting therapeutic 
modality that shows rapid response and improvement with few side 
effects, and may lead to avoidance of systemic immunosuppression.
In the present study, a significant improvement was found with 
respect to keratitis, limbal involvement, and the appearance of the 
papillae following the supratarsal injection of 20 mg triamcinolone 
acetonide in severe cases of VKC in children, thus reducing the need 
for topical corticosteroids and their associated side effects. The in-
jection indicated a more consistent result than did topical steroids 
alone, with more permanent control of the disease, or at least re-
duced intensity of the symptoms to be controlled henceforth with 
recurrent crisis. We recognize that VKC is a bilateral yet asymmetric 
disease, which is why the injection of triamcinolone was considered 
separately for each eye. 
The rapid, initial symptomatic relief from supratarsal injection 
of triamcinolone acetonide is the result of local reduction of inflam-
mation(8). Acetonide of triamcinolone has the capacity to inhibit 
Table 2. Results of supratarsal triamcinolone acetonide injection in 
vernal keratoconjunctivitis in children (n=17)
VKC patients %
Signs and symptoms improvement 17 100.0
Early recurrence (1 month) 06 035.0
Need of reinjection 06 035.0
Months after 1st injection Mean 13.1 (SD 11.3)
Intraocular pressure elevation 01 005.8
intercellular adhesion molecule (ICAM-1), tumor necrosis factor, 
interleukins 1, 2, 6, and 8, and T cell-mediated cytotoxicity(7) factors 
that have been previously insinuated in the pathogenesis of VKC(10).
This treatment is also indicated for patients with problems of 
compliance to topical treatment due to high medication costs, diffi-
culties in administering the drops to children, or a lack of responsibi-
lity or understanding by the caregiver. 
Topical immunomodulators such as tacrolimus and cyclosporine 
A also represent options for long-term treatment of these patients, 
showing side effects that are generally transient and with no rebound 
effect following discontinuation of the drug(11). However, these drugs 
are very expensive in Brazil, and in some cases, recurrent allergy crises 
occur even while using them. Hence, when the patient is unable to 
use immunomodulators due to intolerable side effects or high cost, 
supratarsal injection can be a suitable option.
The main concern regarding the use of triamcinolone for the 
treatment of VKC is its influence on IOP. However, only one patient 
with VKC experienced elevation in IOP (≥5 mmHg) in our study, and 
other studies have shown similar rates of this complication(7,9). Other 
complications of the supratarsal triamcinolone injection have been 
reported(9), including blepharoptosis, skin depigmentation, infec-
tions, motility disturbance, and conjunctival scarring; none of these 
complications were observed in our patients. 
The major difficulty encountered herein was convincing the 
children to cooperate with the procedure. In some cases, the child 
would not allow the injection in the second eye or refused a repeated 
injection a few months later (when applicable). Proper care should be 
taken to hold the patient’s hand tightly in order to avoid accidents 
with the needle. Uncooperative children can be put under sedation 
to safely perform the procedure.
In conclusion, the treatment of severe acute VKC in children 
with supratarsal injection of 20 mg triamcinolone acetonide showed 
satisfactory results and was well tolerated by patients, suggesting 
that this treatment may constitute a safe option for severe and chal-
lenging cases. A significant improvement was found in ocular allergy 
symptoms and signs, with a reduction in the frequency of acute re-
currences, albeit not leading to full disease remission. Similar results 
were reported in other studies(3,6-9).
Further studies with a larger number of patients and a control 
group are warranted to better assess the efficacy and safety of supra-
tarsal injections of different doses of triamcinolone acetonide in the 
management of VKC and other types of ocular allergies. 
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Figure 2. Efficacy of supratarsal triamcinolone injection after 1 week on the upper tarsal 
conjunctiva and cornea. A) Inflammation of the upper tarsal conjunctiva showing the 
Maxwell Lyon’s sign and inflamed giant papillae. B) Improvement of conjunctival conges-
tion, flattened giant papillae, mucous discharge, and edema after treatment. C) Diffuse 
keratitis was noted before treatment. D) Clear cornea with no keratitis after treatment.
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